X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-03-15 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $12.71 | +250 | 257,745 | 0% | +$3,178 | ||||||
2023-03-10 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $12.12 | +1,000 | 2,737,486 | 0% | +$12,120 | ||||||
2023-02-24 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $15.40 | +250 | 257,495 | 0% | +$3,849 | ||||||
2023-02-17 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $16.53 | +600 | 2,736,486 | 0% | +$9,918 | ||||||
2023-02-10 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $18.68 | +1,000 | 2,735,886 | 0% | +$18,680 | ||||||
2023-02-03 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $20.84 | +250 | 257,245 | 0% | +$5,210 | ||||||
2023-01-27 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $19.35 | +2,000 | 2,734,886 | 0% | +$38,700 | ||||||
2023-01-27 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $19.20 | +250 | 256,995 | 0% | +$4,800 | ||||||
2023-01-20 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $17.37 | +1,500 | 2,732,886 | 0% | +$26,055 | ||||||
2023-01-13 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $16.50 | +250 | 256,745 | 0% | +$4,125 | ||||||
2023-01-06 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $15.18 | +1,500 | 2,731,386 | 0% | +$22,770 | ||||||
2022-12-29 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $15.19 | +4,000 | 2,729,886 | 0% | +$60,760 | ||||||
2022-12-16 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $13.01 | +1,000 | 2,725,886 | 0% | +$13,010 | ||||||
2022-12-16 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $12.94 | +250 | 256,495 | 0% | +$3,235 | ||||||
2022-12-09 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $13.11 | +2,000 | 2,724,886 | 0% | +$26,220 | ||||||
2022-12-02 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $13.84 | +1,000 | 2,722,886 | 0% | +$13,840 | ||||||
2022-12-02 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $13.98 | +250 | 256,245 | 0% | +$3,495 | ||||||
2022-11-02 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $8.79 | +2,000 | 2,721,886 | 0% | +$17,580 | ||||||
2022-10-14 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.75 | +3,000 | 2,719,886 | 0% | +$29,250 | ||||||
2022-10-07 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.72 | +2,000 | 2,716,886 | 0% | +$19,440 | ||||||
2022-09-30 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.46 | +1,000 | 2,714,886 | 0% | +$9,460 | ||||||
2022-09-29 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.23 | +1,000 | 2,713,886 | 0% | +$9,230 | ||||||
2022-06-24 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.13 | +29,000 | 5,419,307 | +1% | +$264,770 | ||||||
2022-06-16 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $7.13 | +8,000 | 2,683,886 | 0% | +$57,040 | ||||||
2022-06-14 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $7.91 | +12,000 | 2,675,886 | 0% | +$94,920 | ||||||
2022-06-10 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $8.33 | +12,000 | 2,663,886 | 0% | +$99,960 | ||||||
2022-06-09 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $10.90 | +4,500 | 1,243,453 | 0% | +$49,050 | ||||||
2022-06-07 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $8.55 | +6,000 | 1,238,953 | 0% | +$51,300 | ||||||
2022-06-03 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $8.35 | +9,250 | 1,232,953 | +1% | +$77,238 | ||||||
2022-06-02 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $7.38 | +6,774 | 1,223,703 | +1% | +$49,992 | ||||||
2022-04-25 | GLSI | Daugherty Frank Joseph | Chief Medical Officer | P - Purchase | $16.25 | +1,000 | 90,121 | +1% | +$16,250 | ||||||
2022-04-21 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $16.09 | +6,000 | 1,216,929 | 0% | +$96,540 | ||||||
2022-04-19 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $16.74 | +6,000 | 1,210,929 | 0% | +$100,440 | ||||||
2022-04-19 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $16.74 | +500 | 255,995 | 0% | +$8,370 | ||||||
2022-02-11 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $19.80 | +5,500 | 1,204,929 | 0% | +$108,900 | ||||||
2022-02-04 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $19.59 | +5,000 | 1,199,429 | 0% | +$97,950 | ||||||
2022-01-31 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $18.47 | +500 | 255,495 | 0% | +$9,235 | ||||||
2022-01-21 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $16.33 | +500 | 254,995 | 0% | +$8,165 | ||||||
2022-01-21 | GLSI | Hallock Kenneth | Dir | P - Purchase | $16.32 | +300 | 397,304 | 0% | +$4,896 | ||||||
2022-01-18 | GLSI | Thompson Jaye | VP Clinical Reg. Affairs | P - Purchase | $18.87 | +500 | 254,495 | 0% | +$9,435 | ||||||
2022-01-13 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $19.99 | +1,000 | 1,194,429 | 0% | +$19,990 | ||||||
2022-01-13 | GLSI | Thompson Jaye | VP Clinical Reg. Affairs | P - Purchase | $19.99 | +1,000 | 253,995 | 0% | +$19,990 | ||||||
2022-01-13 | GLSI | Daugherty Frank Joseph | Chief Medical Officer | P - Purchase | $19.99 | +1,000 | 89,121 | +1% | +$19,990 | ||||||
2022-01-03 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $23.82 | +2,050 | 1,193,429 | 0% | +$48,831 | ||||||
2021-12-14 | GLSI | Patel Snehal | CEO, CFO, 10% | P - Purchase | $27.17 | +1,840 | 1,191,379 | 0% | +$49,992 | ||||||
2021-12-14 | GLSI | Daugherty Frank Joseph | Chief Medical Officer | P - Purchase | $26.99 | +1,111 | 88,121 | +1% | +$29,983 | ||||||
2021-12-14 | GLSI | McWilliams David | Dir | P - Purchase | $27.56 | +200 | 620,301 | 0% | +$5,512 | ||||||
2021-04-13 | GLSI | Patel Snehal | CEO, CFO | P - Purchase | $36.98 | +2,700 | 7,782,458 | 0% | +$99,853 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |